Bayer appoints new Chairman & Chief Executive Officer in ANZ

Sydney, 1 February, 2024 – 
Bayer is pleased to announce Manoj Saxena as the Chairman and Chief Executive Officer of the Bayer Group in Australia and New Zealand (ANZ).

Ashraf Al-Ouf (left), Manoj Saxena (right)
Left: Ashraf Al-Ouf, SVP, Region Head, Pharmaceuticals Commercial Operations Bayer APAC
Right: Manoj Saxena, CEO Bayer ANZ and Country Division Head ANZ for the Pharmaceutical division

 

Manoj succeeds Ashraf Al-Ouf who is taking on the role of SVP, Region Head, Pharmaceuticals Commercial Operations for Bayer in APAC.

 

Mr Saxena stepped into his new position from 1 February, 2024. In addition to his role as the new Chief Executive Officer for Australia and New Zealand, Manoj will also serve as the Country Division Head ANZ for the Pharmaceutical division.

 

Mr Saxena said he is thrilled to take the leadership position at Bayer ANZ, “I am so proud to join a team that is driving significant improvements for patients, customers and farmers in Australia and New Zealand. As a life science company, I am deeply committed to our focus on advancing health and agriculture, while driving sustainable outcomes in rural and remote communities.”

 

Mr Saxena leaves his post as Country Division Head Pharmaceuticals for South Asia and brings with him a wealth of experience and a proven track record within Bayer. His journey with Bayer began in 2009 when he joined Bayer India as the Business Unit Head. Over the past 26 years, Mr Saxena has played pivotal roles in various countries, including Vietnam, Malaysia/Singapore, and India/South Asia. He also is a member of global PH DEI council and sponsor for local community within South Asia. 

 

As Manoj Saxena takes on the new role, outgoing ANZ Chief Executive Officer Ashraf Al-Ouf will assume the role of SVP, Region Head, Pharmaceuticals Commercial Operations APAC, based in Singapore, effective 1 February, 2024.

 

Ashraf Al-Ouf’s career with Bayer spans more than 26 years across multiple markets including Australia, Malaysia, Indonesia and Japan. Bayer ANZ has greatly benefited from his expertise since first joining the local organisation in 2007. A people focused leader, Ashraf has been unwavering in his focus on people and culture and in his commitment to advancing Bayer’s mission of Health for All, Hunger for None.

 

“To all Bayer ANZ, thank you for your hard work, resilience and unwavering commitment to excellence. I'm confident that you will continue to thrive and reach new heights. Wishing you and Manoj all enduring success in 2024 and beyond,” Mr Al-Ouf said.

 

About Bayer 
Bayer is a global enterprise with core competencies in the life science fields of health care, nutrition and agriculture. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. The company has operated in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians. Locally, Bayer currently employs almost 700 people across the country and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQI+, generations, disability and race. For more information, go to www.bayer.com.au.

 

Contact:
Emma Orpilla, phone + 61 459 198 470
emma.orpilla@bayer.com

 

Melanie Roukoz, phone +61 458 524422
Email: melanie.roukoz@bayer.com

 

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.